flow study semaglutide FLOW- the Visual Abstract — NephJC Semaglutide in patients with overweight
Description
95% CI, 0.240.35
The wide use of these drugs and their adverse effects, although rare, need to be considered and calculated by patients who are using the drugs for weight
Results disclaimer: Individual results may vary
Like many others, these typically follow a controversies conference - in this case one from 2015 (Perkovic et al, Kidney Int 2016)
